PubMed

Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline.

Irwin N, Flatt PR, Patterson S, Green BD.

Eur J Pharmacol. 2009 Nov 14. [Epub ahead of print]PMID: 19917278 [PubMed - as supplied by publisher]Related articles

Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.

McKillop AM, Duffy NA, Lindsay JR, Green BD, Patterson S, O'Harte FP, Bell PM, Flatt PR.

Eur J Endocrinol. 2009 Dec;161(6):877-85. Epub 2009 Sep 15.PMID: 19755410 [PubMed - in process]Related articles

Therapeutic potential for GIP receptor agonists and antagonists.

Irwin N, Flatt PR.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):499-512.PMID: 19748067 [PubMed - in process]Related articles

Terminalia bellirica stimulates the secretion and action of insulin and inhibits starch digestion and protein glycation in vitro.

Kasabri V, Flatt PR, Abdel-Wahab YH.

Br J Nutr. 2009 Sep 1:1-6. [Epub ahead of print]PMID: 19723351 [PubMed - as supplied by publisher]Related articles

Effect of RU486 on Hepatic and Adipocyte Gene Expression Improves Diabetes Control in Obesity-type 2 Diabetes.

Taylor AI, Frizzell N, McKillop AM, Flatt PR, Gault VA.

Horm Metab Res. 2009 Aug 10. [Epub ahead of print]PMID: 19670152 [PubMed - as supplied by publisher]Related articles

Toll-like receptor agonist induced changes in clonal rat BRIN-BD11 beta-cell insulin secretion and signal transduction.

Kiely A, Robinson A, McClenaghan NH, Flatt PR, Newsholme P.

J Endocrinol. 2009 Sep;202(3):365-73. Epub 2009 Jun 24.PMID: 19553279 [PubMed - indexed for MEDLINE]Related articles

Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications.

Irwin N, Flatt PR.

Diabetologia. 2009 Sep;52(9):1724-31. Epub 2009 Jun 17.PMID: 19533083 [PubMed - in process]Related articles

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR, Gault VA.

Biochem Pharmacol. 2009 Oct 15;78(8):1008-16. Epub 2009 Jun 10.PMID: 19523458 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.

Irwin N, McClean PL, Hunter K, Flatt PR.

Diabetes Obes Metab. 2009 Jun;11(6):603-10. Epub 2009 Apr 13.PMID: 19515180 [PubMed - in process]Related articles

A glycine-leucine-rich peptide structurally related to the plasticins from skin secretions of the frog Leptodactylus laticeps (Leptodactylidae).

Conlon JM, Abdel-Wahab YH, Flatt PR, Leprince J, Vaudry H, Jouenne T, Condamine E.

Peptides. 2009 May;30(5):888-92. Epub 2009 Jan 22.PMID: 19428765 [PubMed - indexed for MEDLINE]Related articles

Overexpression of the malate-aspartate NADH shuttle member Aralar1 in the clonal beta-cell line BRIN-BD11 enhances amino-acid-stimulated insulin secretion and cell metabolism.

Bender K, Maechler P, McClenaghan NH, Flatt PR, Newsholme P.

Clin Sci (Lond). 2009 Sep 1;117(9):321-30.PMID: 19344310 [PubMed - indexed for MEDLINE]Related articles

Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

Flatt PR, Bailey CJ, Green BD.

Curr Drug Metab. 2009 Feb;10(2):125-37. Review.PMID: 19275548 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.

Irwin N, Hunter K, Frizzell N, Flatt PR.

Regul Pept. 2009 Feb 25;153(1-3):70-6. Epub 2008 Dec 3.PMID: 19073224 [PubMed - indexed for MEDLINE]Related articles

Prolonged GIP receptor activation using stable mini-PEGylated GIP improves glucose homeostasis and beta-cell function in age-related glucose intolerance.

Kerr BD, Irwin N, Flatt PR, Gault VA.

Peptides. 2009 Feb;30(2):219-25. Epub 2008 Nov 5.PMID: 19026698 [PubMed - indexed for MEDLINE]Related articles

Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes.

Irwin N, McClean PL, Patterson S, Hunter K, Flatt PR.

Biol Chem. 2009 Jan;390(1):75-80.PMID: 18937625 [PubMed - indexed for MEDLINE]Related articles

A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity.

Abdel-Wahab YH, Power GJ, Flatt PR, Woodhams DC, Rollins-Smith LA, Conlon JM.

Peptides. 2008 Dec;29(12):2136-43. Epub 2008 Sep 21.PMID: 18848963 [PubMed - indexed for MEDLINE]Related articles

Prolonged L-alanine exposure induces changes in metabolism, Ca(2+) handling and desensitization of insulin secretion in clonal pancreatic beta-cells.

McClenaghan NH, Scullion SM, Mion B, Hewage C, Malthouse JP, Flatt PR, Newsholme P, Brennan L.

Clin Sci (Lond). 2009 Feb;116(4):341-51.PMID: 18702613 [PubMed - indexed for MEDLINE]Related articles

(Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy.

McClean PL, Irwin N, Hunter K, Gault VA, Flatt PR.

Br J Pharmacol. 2008 Nov;155(5):690-701. Epub 2008 Aug 11.PMID: 18695644 [PubMed - indexed for MEDLINE]Related articlesFree article

Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?

Flatt PR.

Diabet Med. 2008 Jul;25(7):759-64.PMID: 18513308 [PubMed - indexed for MEDLINE]Related articles

Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes.

Flatt PR, Bailey CJ, Green BD.

Front Biosci. 2008 May 1;13:3648-60. Review.PMID: 18508462 [PubMed - indexed for MEDLINE]Related articles

A potent, non-toxic insulin-releasing peptide isolated from an extract of the skin of the Asian frog, Hylarana guntheri (Anura:Ranidae).

Conlon JM, Power GJ, Abdel-Wahab YH, Flatt PR, Jiansheng H, Coquet L, Leprince J, Jouenne T, Vaudry H.

Regul Pept. 2008 Nov 29;151(1-3):153-9. Epub 2008 Apr 13.PMID: 18501981 [PubMed - indexed for MEDLINE]Related articles

C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.

Gault VA, Kerr BD, Irwin N, Flatt PR.

Biochem Pharmacol. 2008 Jun 15;75(12):2325-33. Epub 2008 Mar 26.PMID: 18455149 [PubMed - indexed for MEDLINE]Related articles

Iterative exposure of clonal BRIN-BD11 cells to ninhydrin enables selection of robust toxin-resistant cells but with decreased gene expression of insulin secretory function.

Liu HK, McCluskey JT, McClenghan NH, Flatt PR.

Pancreas. 2008 Apr;36(3):294-301.PMID: 18362844 [PubMed - indexed for MEDLINE]Related articles

Daily administration of the GIP-R antagonist (Pro3)GIP in streptozotocin-induced diabetes suggests that insulin-dependent mechanisms are critical to anti-obesity-diabetes actions of (Pro3)GIP.

McClean PL, Gault VA, Irwin N, McCluskey JT, Flatt PR.

Diabetes Obes Metab. 2008 Apr;10(4):336-42.PMID: 18333892 [PubMed - indexed for MEDLINE]Related articles

Comparison of independent and combined chronic metabolic effects of GIP and CB1 receptor blockade in high-fat fed mice.

Irwin N, Hunter K, Flatt PR.

Peptides. 2008 Jun;29(6):1036-41. Epub 2008 Jan 18.PMID: 18291559 [PubMed - indexed for MEDLINE]Related articles

Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.

Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA.

Biol Chem. 2008 Apr;389(4):441-5.PMID: 18225986 [PubMed - indexed for MEDLINE]Related articles

Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice.

Irwin N, Hunter K, Frizzell N, Flatt PR.

Eur J Pharmacol. 2008 Feb 26;581(1-2):226-33. Epub 2007 Dec 14.PMID: 18191122 [PubMed - indexed for MEDLINE]Related articles

Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-substituted analogue.

Abdel-Wahab YH, Power GJ, Ng MT, Flatt PR, Conlon JM.

Biol Chem. 2008 Feb;389(2):143-8.PMID: 18163889 [PubMed - indexed for MEDLINE]Related articles

Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets.

Cassidy RS, Irwin N, Flatt PR.

Biol Chem. 2008 Feb;389(2):189-93.PMID: 18163884 [PubMed - indexed for MEDLINE]Related articles

Incretin hormone mimetics and analogues in diabetes therapeutics.

Green BD, Flatt PR.

Best Pract Res Clin Endocrinol Metab. 2007 Dec;21(4):497-516. Review.PMID: 18054732 [PubMed - indexed for MEDLINE]Related articles

Streptozotocin-resistant BRIN-BD11 cells possess wide spectrum of toxin tolerance and enhanced insulin-secretory capacity.

Liu HK, McCluskey JT, McClenghan NH, Flatt PR.

Endocrine. 2007 Aug;32(1):20-9. Epub 2007 Sep 29.PMID: 17992598 [PubMed - indexed for MEDLINE]Related articles

Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic beta-cell line.

Kiely A, McClenaghan NH, Flatt PR, Newsholme P.

J Endocrinol. 2007 Oct;195(1):113-23.PMID: 17911403 [PubMed - indexed for MEDLINE]Related articlesFree article

Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.

McKillop AM, Duffy NA, Lindsay JR, O'Harte FP, Bell PM, Flatt PR.

Diabetes Res Clin Pract. 2008 Jan;79(1):79-85. Epub 2007 Sep 29.PMID: 17904681 [PubMed - indexed for MEDLINE]Related articles

Insulin releasing properties of the temporin family of antimicrobial peptides.

Abdel-Wahab YH, Marenah L, Flatt PR, Conlon JM.

Protein Pept Lett. 2007;14(7):702-7.PMID: 17897097 [PubMed - indexed for MEDLINE]Related articles

Comparison of the metabolic effects of GIP receptor antagonism and PYY(3-36) receptor activation in high fat fed mice.

Irwin N, Hunter K, Flatt PR.

Peptides. 2007 Nov;28(11):2192-8. Epub 2007 Aug 19.PMID: 17884253 [PubMed - indexed for MEDLINE]Related articles

GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.

McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR.

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1746-55. Epub 2007 Sep 11.PMID: 17848629 [PubMed - indexed for MEDLINE]Related articlesFree article

Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs?

Flatt PR.

Diab Vasc Dis Res. 2007 Jun;4(2):151-3.PMID: 17654450 [PubMed - indexed for MEDLINE]Related articles

Effects of subchronic treatment with the long-acting glucose-dependent insulinotropic polypeptide receptor agonist, N-AcGIP, on glucose homeostasis in streptozotocin-induced diabetes.

Gault VA, McClean PL, Irwin N, Power GJ, McCluskey JT, Flatt PR.

Pancreas. 2007 Jul;35(1):73-9.PMID: 17575548 [PubMed - indexed for MEDLINE]Related articles

Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1.

Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'Harte FP, Flatt PR.

Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86. Epub 2007 May 13.PMID: 17573070 [PubMed - indexed for MEDLINE]Related articles

Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets.

Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR.

Diabetologia. 2007 Aug;50(8):1752-62. Epub 2007 Jun 9.PMID: 17558485 [PubMed - indexed for MEDLINE]Related articles

Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.

Irwin N, McClean PL, Flatt PR.

J Pept Sci. 2007 Jun;13(6):400-5.PMID: 17486662 [PubMed - indexed for MEDLINE]Related articles

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Irwin N, McClean PL, O'Harte FP, Gault VA, Harriott P, Flatt PR.

Diabetologia. 2007 Jul;50(7):1532-40. Epub 2007 May 8.PMID: 17486314 [PubMed - indexed for MEDLINE]Related articles

Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists.

Gault VA, Hunter K, Irwin N, Green BD, Greer B, Harriott P, O'Harte FP, Flatt PR.

Arch Biochem Biophys. 2007 May 15;461(2):263-74. Epub 2007 Mar 28.PMID: 17428436 [PubMed - indexed for MEDLINE]Related articles

Major metabolic homocysteine-derivative, homocysteine thiolactone, exerts changes in pancreatic beta-cell glucose-sensing, cellular signal transduction and integrity.

Patterson S, Flatt PR, McClenaghan NH.

Arch Biochem Biophys. 2007 May 15;461(2):287-93. Epub 2007 Mar 2.PMID: 17376398 [PubMed - indexed for MEDLINE]Related articles

Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice.

Green BD, Irwin N, Flatt PR.

Peptides. 2007 May;28(5):981-7. Epub 2007 Feb 12.PMID: 17350140 [PubMed - indexed for MEDLINE]Related articles

Comparison of the anti-diabetic effects of GIP- and GLP-1-receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N-AcGIP and exendin(1-39)amide.

Irwin N, McClean PL, Cassidy RS, O'harte FP, Green BD, Gault VA, Harriott P, Flatt PR.

Diabetes Metab Res Rev. 2007 Oct;23(7):572-9.PMID: 17315241 [PubMed - indexed for MEDLINE]Related articles

Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and absorption, and enhancing insulin action.

Hannan JM, Ali L, Rokeya B, Khaleque J, Akhter M, Flatt PR, Abdel-Wahab YH.

Br J Nutr. 2007 Mar;97(3):514-21.PMID: 17313713 [PubMed - indexed for MEDLINE]Related articles

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

O'Harte FP, Hunter K, Gault VA, Irwin N, Green BD, Greer B, Harriott P, Bailey CJ, Flatt PR.

Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1674-82. Epub 2007 Feb 13.PMID: 17299087 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice.

Parker JC, Irwin N, Lavery KS, Green BD, O'Harte FP, Gault VA, Flatt PR.

Biol Chem. 2007 Feb;388(2):221-6.PMID: 17261085 [PubMed - indexed for MEDLINE]Related articles

Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes.

Gault VA, Hunter K, Irwin N, Greer B, Green BD, Harriott P, O'Harte FP, Flatt PR.

Biol Chem. 2007 Feb;388(2):173-9.PMID: 17261080 [PubMed - indexed for MEDLINE]Related articles